Viridian Therapeutics (VRDN) Gets a Buy from Stifel Nicolaus
Stifel Nicolaus analyst Alex Thompson CFA maintained a Buy rating on Viridian Therapeutics (VRDN – Research Report) today and set a price ...
Viridian Therapeutics Primed for Market Domination with Promising Veligrotug Results and Strategic Positioning
Leerink Partners analyst Thomas Smith has maintained their bullish stance on VRDN stock, giving a Buy rating on January 14.Invest with ...
Viridian Therapeutics, Inc. (NASDAQ:VRDN) Receives $35.70 Average Price Target from Analysts
Viridian Therapeutics, Inc. (NASDAQ:VRDN – Get Free Report) has earned an average recommendation of “Moderate Buy” from the twelve research firms that are currently covering the company, Ratings ...
Viridian Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
Viridian Therapeutics, Inc. (Nasdaq: VRDN), a biopharmaceutical company focused on discovering and developing potential best-in-class medicines for serious and rare diseases, today announced that a ...
ADVFN20d
Viridian Therapeutics Highlights 2025 Corporate Priorities Following Positive Phase 3 Topline Data in Thyroid Eye Disease
VRDN Viridian Therapeutics Inc Viridian Therapeutics Highlights 2025 Corporate Priorities Following Positive Phase 3 Topline Data in Thyroid Eye Disease - Veligrotug, ...
Morningstar5d
Viridian Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
Viridian Therapeutics, Inc. (Nasdaq: VRDN), a biopharmaceutical company focused on discovering and developing potential best-in-class medicines for serious and rare diseases, today announced that ...
Wall Street Journal28d
Viridian Therapeutics Inc.
The Price to Earnings (P/E) ratio, a key valuation measure, is calculated by dividing the stock's most recent closing price by the sum of the diluted earnings per share from continuing operations ...